source
- Samsung Biologics to acquire Swiss CDMO PolyPeptide for $1.8 billion, entering peptide API marketSamsung Biologics announced a plan to purchase Swiss contract development and manufacturing organization PolyPeptide for $1.8 billion in cash. The acquisition will extend Samsung Biologics' manufa…
- Scribe Therapeutics targets $96 million IPO to fund PCSK9 gene-silencing programScribe Therapeutics, a Bay Area biotech focused on genetic medicines, filed with the SEC outlining plans for an initial public offering on Nasdaq. The company aims to sell 7.1 million shares at $1…